Scientific Publications
- PMID: 20111599
- Title: Phase 1 safety and immunogenicity evaluation of ADMVA a multigenic modified vaccinia Ankara HIV 1 B C candidate vaccine
- Abstract: We conducted a Phase I dose-escalation trial of ADMVA, a Clade-B'/C-based HIV-1 candidate vaccine expressing env, gag, pol, nef, and tat in a modified vaccinia Ankara viral vector. Sequences were derived from a prevalent circulating HIV-1 recombinant form in Yunnan, China, an area of high HIV incidence. The objective was to evaluate the safety and immunogenicity of ADMVA in human volunteers.
- Date: 1970-08-21
- Year: 2010
- Journal: PLoS ONE
- PMID Author: Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa , Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD
Phase 1 safety and immunogenicity evaluation of ADMVA a multigenic modified vaccinia Ankara HIV 1 B C candidate vaccine
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS ONE 2010;5(1):e8816 doi: 10.1371/journal.pone.0008816
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
